Sotera Health (NASDAQ:SHC) Updates FY24 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $0.67-0.75 for the period, compared to the consensus earnings per share estimate of $0.72. The company issued revenue guidance of $1.09-1.11 billion, compared to the consensus revenue estimate of $1.11 billion. Sotera Health also updated its FY 2024 guidance to 0.670-0.750 EPS.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Tuesday, August 6th. Barclays increased their target price on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Finally, Citigroup increased their target price on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Sotera Health has an average rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Stock Up 1.2 %

SHC traded up $0.19 during trading hours on Friday, hitting $16.02. 40,755 shares of the company’s stock were exchanged, compared to its average volume of 1,301,293. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44. The firm has a 50 day moving average of $15.96 and a 200 day moving average of $13.69. The firm has a market cap of $4.54 billion, a P/E ratio of 63.32 and a beta of 2.08. The company has a current ratio of 2.88, a quick ratio of 2.59 and a debt-to-equity ratio of 4.91.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. During the same period in the prior year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts predict that Sotera Health will post 0.64 EPS for the current fiscal year.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the sale, the director now owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 55.12% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.